NOVEL 2-SUBSTITUTED-5-(4-CHLORO-2-PHENOXY)PHENYL-1,3,4- OXADIAZOLE DERIVATIVES, LIGANDS OF GABAA/BENZODIAZEPINE RECEPTOR COMPLEX: DESIGN, SYNTHESIS, RADIOLIGAND BINDING ASSAY, AND PHARMACOLOGICAL EVALUATION.

Rezaee, Elham; Ahmadi, Fatemeh; Shabaninia, Mahsa; Khoramjouy, Mona; Farsani, Zahra Azizi; Shahhosseini, Soraya; Tabatabai, Sayyed Abbas; Faizi, Mehrdad

Agonists of Benzodiazepine (BZD) receptor are exhaustively used in the control of muscle spasms, seizure, anxiety, and insomnia. BZDs have some unwanted effects; therefore, the development of new BZD receptor agonists with better efficacy and fewer unwanted effects is one of the subjects of interest. In this study, based on the pharmacophore/receptor model of the BZD binding site of GABAA receptors, a series of new 2-substituted-5-(4-chloro2-phenoxy)phenyl-1,3,4-oxadiazole derivatives (6a-f) were designed. Energy minima conformers of the designed compounds and diazepam were well matched in conformational analysis and showed proper interaction with the BZD-binding site of the GABAA receptor model (α1β2ϒ2) in docking studies. The designed compounds were synthesized in acceptable yield and evaluated for their in vitro affinity to the benzodiazepine receptor of rat brains by radioligand receptor binding assay. The results demonstrated that the affinities of most of the novel compounds were even higher than diazepam. The novel compound 6a with the best affinity in radioligand receptor binding assay (Ki=0.44 nM and IC50= 0.73±0.17 nM) had considerable hypnotic activity and weak anticonvulsant and anxiolytic effects with no negative effect on memory in animal models. Flumazenil as a selective benzodiazepine receptor antagonist was able to prevent hypnotic and anticonvulsant effects of 6a indicating the role of BZD receptors in these effects.

BENZODIAZEPINE receptors; RADIOLIGAND assay; BINDING site assay; BENZODIAZEPINES; GABA receptors; BINDING sites; LIGANDS (Chemistry)

EXCLI Journal, 2023, Vol 22, p250

1611-2156

Academic Journal

10.17179/excli2022-5639